The FDA has accepted Genentech’s biologics license application under priority review for faricimab to treat neovascular age-related macular degeneration and diabetic macular edema.
The submission was also accepted for diabetic retinopathy, and the European Medicines Agency validated the marketing authorization application for the drug for wet AMD and DME.
“If approved, faricimab would be the first in a new class of eye medicines targeting two key pathways that drive retinal disorders, with the potential to offer durable vision outcomes with fewer eye injections than the current